197 related articles for article (PubMed ID: 27059733)
21. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
22. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
[TBL] [Abstract][Full Text] [Related]
23. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
24. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.
Loessner D; Quent VM; Kraemer J; Weber EC; Hutmacher DW; Magdolen V; Clements JA
Gynecol Oncol; 2012 Dec; 127(3):569-78. PubMed ID: 22964375
[TBL] [Abstract][Full Text] [Related]
25. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.
Zhang SF; Wang XY; Fu ZQ; Peng QH; Zhang JY; Ye F; Fu YF; Zhou CY; Lu WG; Cheng XD; Xie X
Autophagy; 2015; 11(2):225-38. PubMed ID: 25607466
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
27. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
28. LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells.
Zhang M; Liu S; Fu C; Wang X; Zhang M; Liu G; Dai C; Gong Z; Xu H; Fu Z; Xu P; Xu J; Jia X
Cancer Biother Radiopharm; 2019 Jun; 34(5):316-324. PubMed ID: 30892073
[No Abstract] [Full Text] [Related]
29. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
31. Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain.
Kang HG; Kim DH; Kim SJ; Cho Y; Jung J; Jang W; Chun KH
Oncotarget; 2016 Oct; 7(42):68229-68241. PubMed ID: 27626163
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
Xiang F; Ni Z; Zhan Y; Kong Q; Xu J; Jiang J; Wu R; Kang X
Tumour Biol; 2016 May; 37(5):6017-25. PubMed ID: 26596839
[TBL] [Abstract][Full Text] [Related]
33. Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling.
Sun T; Liu Y; Li M; Yu H; Piao H
Mol Cell Probes; 2020 Oct; 53():101602. PubMed ID: 32447047
[TBL] [Abstract][Full Text] [Related]
34. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
35. Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
Shen Y; Zhang XY; Chen X; Fan LL; Ren ML; Wu YP; Chanda K; Jiang SW
Oncol Rep; 2017 Jan; 37(1):219-226. PubMed ID: 27878277
[TBL] [Abstract][Full Text] [Related]
36. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.
Kelly MG; Alvero AB; Chen R; Silasi DA; Abrahams VM; Chan S; Visintin I; Rutherford T; Mor G
Cancer Res; 2006 Apr; 66(7):3859-68. PubMed ID: 16585214
[TBL] [Abstract][Full Text] [Related]
37. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
[TBL] [Abstract][Full Text] [Related]
38. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.
Abuharbeid S; Apel J; Zugmaier G; Knabbe C; Sander M; Gilbert S; Czubayko F; Aigner A
Naunyn Schmiedebergs Arch Pharmacol; 2005 Feb; 371(2):141-51. PubMed ID: 15700118
[TBL] [Abstract][Full Text] [Related]
40. Rhus verniciflua Stokes (RVS) and butein induce apoptosis of paclitaxel-resistant SKOV-3/PAX ovarian cancer cells through inhibition of AKT phosphorylation.
Choi HS; Kim MK; Choi YK; Shin YC; Cho SG; Ko SG
BMC Complement Altern Med; 2016 Apr; 16():122. PubMed ID: 27121110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
